CRMD logoCRMD
CorMedix Inc

22,558
Loading...
Loading...
News
all
press releases
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
Puma Biotechnology shares rise nearly 30% in three months on rising Nerlynx sales, with key data on pipeline drug alisertib due later this year.
Zacks·1d ago
News Placeholder
More News
News Placeholder
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Zacks·1d ago
News Placeholder
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
Zacks·1d ago
News Placeholder
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
Zacks·4d ago
News Placeholder
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
Zacks·4d ago
News Placeholder
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
Zacks·5d ago
News Placeholder
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
Zacks·7d ago
News Placeholder
CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·7d ago
News Placeholder
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
Zacks·12d ago
News Placeholder
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Zacks·13d ago

Latest CRMD News

View

Advertisement. Remove ads.

Advertisement. Remove ads.